
Alzecure Q3 2024 - Business development on the agenda

Redeye returns with an update following Alzecure's Q3 report. In relation to this update, we make some adjustments to our deal and pipeline assumptions.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Alzecure Q3 2024 - Business development on the agenda](#)